A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
← catalyst calendarNCT06524414 · readout in 254 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
605actual
Sites
68
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-25 | actual | When the study began enrolling |
| Primary completion | 2027-05-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pneumococcal Disease
Interventions
- Biological: PG4
- Biological: 20-valent pneumococcal conjugate vaccine (20vPnC) — also filed as Prevnar 20
- Biological: 15-valent pneumococcal conjugate vaccine (PCV15) — also filed as PCV15
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants reporting local reactions within 7 days after each dose
measured Day 7
Percentage of participants reporting systemic events within 7 days after each dose
measured Day 7
Percentage of participants reporting adverse events (AEs)
measured Dose 1 to 1 month after Dose 3
Percentage of participants reporting AEs
measured Dose 4 to 1 month after Dose 4
Percentage of participants reporting serious adverse events (SAEs)
measured Dose 1 to 6 months after Dose 4
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed